【北京，中国 – BusinessWire】全球领先的人工智能个性化手术医疗科技公司Carlsmed近日宣布，已成功完成由B Capital和US Venture Partners联合主导的C轮融资，募集总额达到5250万美元。此次融资将进一步推动Carlsmed在医疗科技领域的创新步伐。
Carlsmed公司专注于利用人工智能技术提供定制化的手术解决方案，以提高手术精准度和患者康复效果。此轮融资的资金将主要投入到aprevo ®个性化脊柱手术平台的商业化加速中，该平台已经在腰椎融合手术中展现出显著的优势。同时，这笔资金还将用于aprevo ®颈椎融合手术平台的开发，预计该平台将于2025年正式面世，为颈椎手术提供更为精准的个性化方案。
B Capital和US Venture Partners的参与，不仅彰显了投资界对Carlsmed技术与商业模式的认可，也为其在全球医疗市场的拓展提供了强大的资本支持。Carlsmed的首席执行官表示，公司将利用这笔资金加速产品研发，同时扩大市场覆盖，让更多医疗机构和患者受益于人工智能带来的精准医疗进步。
随着医疗科技的快速发展，人工智能在手术领域的应用日益广泛。Carlsmed的aprevo ®平台通过深度学习和数据分析，为医生提供个性化的手术规划，有望大幅减少手术风险，提升患者的生活质量。此次融资的成功，预示着Carlsmed在个性化医疗科技领域的领先地位将进一步巩固，同时也为全球脊柱和颈椎手术治疗开启了新的篇章。
英语如下：
**News Title:** “Carlsmed Raises $52.5 Million in Series C Funding to Accelerate AI-Powered Personalized Spine Surgery Platform”
**Keywords:** Carlsmed, Artificial Intelligence, Surgery Platform
**News Content:**
**Beijing, China – BusinessWire** – Carlsmed, a global leader in AI-driven personalized surgical technologies, recently announced the successful completion of its Series C funding round, co-led by B Capital and US Venture Partners, raising a total of $52.5 million. This financing will fuel Carlsmed’s innovation in the medical technology sector.
Specializing in leveraging artificial intelligence for tailored surgical solutions, Carlsmed aims to enhance surgical precision and patient recovery. The funds raised will primarily support the acceleration of commercialization for the aprevo ® Personalized Spine Surgery Platform, which has demonstrated substantial benefits in lumbar fusion surgeries. Additionally, the capital will facilitate the development of the aprevo ® Cervical Fusion Platform, expected to launch in 2025, offering more precise personalized solutions for cervical surgeries.
The participation of B Capital and US Venture Partners underscores the investment community’s endorsement of Carlsmed’s technology and business model, providing robust capital support for its global expansion in the healthcare market. The company’s CEO stated that the funds will be utilized to hasten product development and broaden market reach, enabling more healthcare institutions and patients to benefit from the advancements in precision medicine facilitated by AI.
As medical technology rapidly progresses, AI’s application in surgical procedures is on the rise. Carlsmed’s aprevo ® platform, through deep learning and data analysis, enables doctors to plan personalized surgeries, potentially reducing surgical risks and improving patients’ quality of life. This successful funding round signals a strengthening of Carlsmed’s leadership position in personalized medical technology and ushers in a new era for global spine and cervical surgery treatments.
【来源】https://www.businesswire.com/news/home/20240318820510/en/Carlsmed-Raises-52.5M-in-Series-C-Financing-to-Advance-Personalized-Spine-Surgery
Views: 1